• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

1V209 Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5759123

MBS5759123 is an inhibitor targeting 1V209. 1V209 is a Toll-like receptor 7 (TLR7) agonist and has anti-tumor effects. More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
1V209, Inhibitor
Full Product Name
1V209
Product Gene Name
Product Synonym Names
TLR7 agonist T7
Form/Format
Solid. Powder
Purity/Purification
98.53%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
359.34
Solubility
DMSO: 83.33mg/mL (231.90mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C16H17N5O5
SMILES
COCCOc1nc(N)c2[nH]c(=O)n(Cc3ccc(cc3)C(O)=O)c2n1
CAS Number
1062444-54-5
Target & IC50
TLR7

Product Categories/Family for 1V209, inhibitor

Structure of 1V209, inhibitor

1V209 Inhibitor – Cat# MBS5759123

Product References and Citations for 1V209, inhibitor

Gold Nanoparticles Coimmobilized with Small Molecule Toll-Like Receptor 7 Ligand and alpha-Mannose as Adjuvants[J]. Bioconjugate Chemistry, 2019, 30(11):2811-2821.
Gold Nanoparticles Coimmobilized with Small Molecule Toll-Like Receptor 7 Ligand and alpha-Mannose as Adjuvants[J]. Bioconjugate Chemistry, 2019, 30(11):2811-2821.
Shinchi H, et al. Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides. Bioconjug Chem. 2015 Aug 19;26(8):1713-23.
Shinchi H, et al. Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides. Bioconjug Chem. 2015 Aug 19;26(8):1713-23.
Battistella C, et al. Delivery of Immunotherapeutic Nanoparticles to Tumors via Enzyme-Directed Assembly. Adv Healthc Mater. 2019 Dec;8(23):e1901105.
Battistella C, et al. Delivery of Immunotherapeutic Nanoparticles to Tumors via Enzyme-Directed Assembly. Adv Healthc Mater. 2019 Dec;8(23):e1901105.

Other Notes

Small volumes of 1V209, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000